Novel Blood-Based Tests for Colorectal Cancer Screening.

Q2 Medicine

Gastrointestinal Endoscopy Clinics of North America Pub Date : 2026-10-01 Epub Date: 2026-04-08 DOI:10.1016/j.giec.2026.02.005

Angela Z Xue, Cyrus Daruwalla, Peter S Liang

引用次数: 0

Abstract

Blood-based tests are a novel colorectal cancer (CRC) screening modality that can potentially improve screening uptake due to greater convenience and patient preference for blood tests. To date, 3 blood-based CRC screening tests have completed large validation studies (Epi proColon, Shield, and the Freenome test). Multi-cancer early detection tests are also actively being investigated for their role in CRC screening. Despite various benefits, blood-based screening tests also have several limitations, including low sensitivity for advanced precancerous lesions, low rates of follow-up colonoscopy after an abnormal test, and concerns about cost-effectiveness.

查看原文本刊更多论文

结直肠癌筛查的新型血液检测

血液检查是一种新型的结直肠癌（CRC）筛查方式，由于更方便和患者对血液检查的偏好，可以潜在地提高筛查的接受度。迄今为止，已有3种基于血液的结直肠癌筛查试验完成了大型验证研究（Epi proColon、Shield和Freenome试验）。多种癌症早期检测测试在CRC筛查中的作用也正在积极研究中。尽管有各种好处，但基于血液的筛查也有一些局限性，包括对晚期癌前病变的敏感性低，异常检查后结肠镜检查的随访率低，以及对成本效益的担忧。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gastrointestinal Endoscopy Clinics of North America Medicine-Gastroenterology

CiteScore

4.30

自引率

0.00%

发文量

期刊介绍： Gastrointestinal Endoscopy Clinics of North America updates you on the latest trends in patient management; keeps you up to date on the newest advances; and provides a sound basis for choosing treatment options. Each issue focuses on a single topic in gastrointestinal endoscopy and is presented under the direction of an experienced guest editor.